Literature DB >> 33542439

Clinical manifestations and visual outcomes associated with ocular toxoplasmosis in a Brazilian population.

Justine R Smith1, João M Furtado2, Sigrid Arruda3, Barbara R Vieira3, Denny M Garcia3, Michelle Araújo3, Milena Simões3, Renata Moreto3, Murilo W Rodrigues3, Rubens Belfort4.   

Abstract

Ocular toxoplasmosis is the leading cause of posterior uveitis worldwide. We conducted an observational study of 262 consecutive individuals (n = 344 eyes) with ocular toxoplasmosis who were followed over a 34-month period. Most subjects were T. gondii IgG + /IgM- (n = 242; 92.4%; 317 eyes), and 140 eyes (40.7%) had active lesions. For eyes in which retinal lesions were active at recruitment and best-corrected visual acuity (BCVA) could be measured (n = 133), 21.0% (n = 28) remained blind (BCVA below 20/400) after inflammation resolved. In these eyes, atypical ocular toxoplasmosis (OR 4.99; 95% CI 1.14-22.85; p = 0.0330), macular lesion (OR 9.95; 95% CI 2.45-47.15; p = 0.0019) and any complication (OR 10.26; 95% CI 3.82-30.67; p < 0.0001) were associated with BCVA below 20/200. For eyes with only inactive lesions at recruitment and BCVA measured (n = 178), 28.1% (n = 50) were blind. In these eyes, having at least one lesion larger than one disc-diameter (OR 6.30; 95% CI 2.28-22.46; p = 0.0013) and macular lesion (OR 5.69; 95% CI 2.53-13.54; p < 0.0001) were associated with BCVA below 20/200. Older age (OR 1.02; 95% CI 1.00-1.05; p = 0.0493) and active disease at presentation (OR 4.74; 95% CI 1.95-12.91; p = 0.0011) were associated with recurrences. Additional clinical attention should be directed towards patients with risk factors for poor visual outcome.

Entities:  

Year:  2021        PMID: 33542439     DOI: 10.1038/s41598-021-82830-z

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  1 in total

1.  Ocular toxoplasmosis: a global reassessment. Part II: disease manifestations and management.

Authors:  Gary N Holland
Journal:  Am J Ophthalmol       Date:  2004-01       Impact factor: 5.258

  1 in total
  2 in total

1.  Structure-activity relationships of Toxoplasma gondii cytochrome bc1 inhibitors.

Authors:  P Holland Alday; Aaron Nilsen; J Stone Doggett
Journal:  Expert Opin Drug Discov       Date:  2022-08-08       Impact factor: 7.050

2.  Posterior segment findings by spectral-domain optical coherence tomography and clinical associations in active toxoplasmic retinochoroiditis.

Authors:  Justine R Smith; João M Furtado; Genevieve F Oliver; Lisia Barros Ferreira; Barbara R Vieira; Sigrid Arruda; Michelle Araújo; Jillian M Carr
Journal:  Sci Rep       Date:  2022-01-21       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.